Jeff Albers

Jeff Albers has extensive leadership experience in the biotechnology sector, serving as the Chairman and former Chief Executive Officer of Blueprint Medicines from 2014 to 2022. Albers is a Venture Partner at Atlas Venture and holds board member positions at Kymera Therapeutics and Spyre Therapeutics. Previously, Albers was the President for the US at Algeta ASA. Academic credentials include a law degree from Georgetown University Law Center and an MBA from Georgetown University McDonough School of Business.